07:00 , Jun 9, 2014 |  BC Week In Review  |  Clinical News

3PO: Phase I started

Advanced Cancer Therapeutics began an open-label, dose-escalation, U.S. Phase I trial to evaluate IV PFK-158, with a starting dose of 24 mg/m 2, in up to 48 patients with advanced solid tumors, including melanoma and...
07:00 , Oct 22, 2012 |  BioCentury  |  Emerging Company Profile

Sprint: Quick start in cancer

Sprint Bioscience AB is leveraging its founders' expertise in fragment-based drug discovery and structural biology to generate leads against novel cancer metabolism and autophagy targets. The biotech hopes to out-license its therapeutics when the molecules...
00:51 , Jul 2, 2010 |  BC Extra  |  Financial News

Advanced Cancer Therapeutics raises $10 million

Advanced Cancer Therapeutics LLC (Louisville, Ky.) raised $10 million in seed financing from undisclosed high net-worth individuals and institutions in Kentucky. The company has three lead programs to treat cancer: small molecule inhibitors for 6-phosphofructo-2-kinase...
07:00 , Mar 10, 2008 |  BC Week In Review  |  Company News

Advanced Cancer Therapeutics, University of Louisville deal

Advanced Cancer Therapeutics received an exclusive, worldwide license from the university to develop and market 3PO and related compounds to treat cancer. The inhibitor of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 ( PFKFB3 ) is in preclinical testing to...